Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

187
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

168
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis

Pages

  1073-1085

Abstract

 Teriparatide is a new agent serves as a treatment of choice for severe post-menopausal osteoporotic patients who are at high risk of fracture or have failed or been intolerant of previous Osteoporosis therapy. The objective of this study is to estimate the cost-utility of Teriparatide compared with no treatment from health system perspective in Iran. A microsimulation model was developed for a cohort of hypothetical Iranian patient population (women aged 70 years, T-score-2. 5 with previous fracture or T-score-3. 0 without prior fracture) over a lifetime horizon. The model consisted of the seven health states. During each cycle, patients could have a fracture, remain healthy, remain in a post-fracture state or die. Background fracture risks, mortality rates, persistence rates, utilities, medical and drug costs were derived using published sources. Total accumulated life-time costs and quality-adjusted life years (QALYs) were estimated. Teriparatide was associated with 4. 786 QALYs and total direct costs of IRR 143, 168, 259 over a lifetime horizon. Compared to no treatment, Teriparatide provided an additional 0. 145 QALY at an incremental cost of IRR 33, 511, 013. The resulting incremental Cost-effectiveness ratio was IRR 230, 333, 030/QALYs gained. The probabilistic analysis showed that accepting a willingness-to-pay 2 and 3 GDP/capita in Iran, the probability of Teriparatide being cost-effective were 51% and 83%, respectively. Compared to no treatment, Teriparatide was indicated to be more costly and associated with fewer fractures, more life-years, and more QALYs. The result showed that Teriparatide may be considered a cost-effective intervention when targeted to the appropriate patients.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    TAHERI, SAEED, Fashami, Fatemeh Mirzayeh, PEIRAVIAN, FARZAD, & YOUSEFI, NAZILA. (2019). Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), 18(2), 1073-1085. SID. https://sid.ir/paper/289092/en

    Vancouver: Copy

    TAHERI SAEED, Fashami Fatemeh Mirzayeh, PEIRAVIAN FARZAD, YOUSEFI NAZILA. Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR)[Internet]. 2019;18(2):1073-1085. Available from: https://sid.ir/paper/289092/en

    IEEE: Copy

    SAEED TAHERI, Fatemeh Mirzayeh Fashami, FARZAD PEIRAVIAN, and NAZILA YOUSEFI, “Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis,” IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), vol. 18, no. 2, pp. 1073–1085, 2019, [Online]. Available: https://sid.ir/paper/289092/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top